· Original article
Celcuity trial results detail gedatolisib breast cancer benefit
Celcuity trial results presented on October 24 detail progression-free survival, tumor responses and treatment discontinuations in advanced breast cancer.
FINANCEVELIX / News
Equities & companies · Page 8
Equities & companies
Listed companies, earnings, corporate developments and equity markets. Company and asset tags identify the subjects of a story.
Read the original source and publication date in each article.
Equities & companies
RSSResults: 1,582 · Page 8 / 132
· Original article
MSIG UK appointments reinforce underwriting and claims team
MSIG UK appointments put Tim Harris in the interim underwriting role, pending regulatory approval, with Stephanie Belcourt joining as Claims Director.
· Original article
Nippon Life adds 162,024 Corebridge shares in October purchase
Nippon Life bought 162,024 Corebridge shares on October 19, 2026, lifting its holding to 130 million shares after a year of continued purchases.
· Original article
Acrisure UK Retail names Andy Tedstone CEO from April 2027
Acrisure UK Retail has named Cobra Network chief Andy Tedstone as CEO from April 2027, with interim leader Andrew Boyce returning to his international role.
· Original article
Everest compliance appointment puts Jamie Taylor in global role
Everest compliance appointment names Jamie Taylor to a global leadership role after a decade at the insurer and reinsurer, including North American regulatory work.
· Original article
DRA Pune expansion targets ₹550 crore residential project
DRA Pune expansion plans centre on a three-acre housing project with ₹550 crore in estimated development value, targeting a larger residential market.
· Original article
Price Forbes Marine names Burnell-Nugent CEO, Kearns chairman
Price Forbes Marine appoints Anthony Burnell-Nugent as CEO, with Paul Kearns becoming chairman as part of the division’s long-term succession plan.
· Original article
Tovecimig results show trial gains, but no survival benefit
Tovecimig results show better response rates and progression-free survival in biliary tract cancer, but no statistically significant overall survival gain.
· Original article
Berkley reinsurance faces 10%–20% pullback as pricing weakens
Berkley reinsurance volume could shrink 10%–20%, management said in October 2026, as competitive pricing tests discipline ahead of January renewals.
· Original article
Bloomberg crypto analytics maps funds to Basel risk groups
Bloomberg crypto analytics flags about 1,700 funds with potential Basel relevance, helping banks identify indirect exposures and assess classifications.
· Original article
OUE REIT earnings: Q3 property income rises 4.6% on hotels
OUE REIT earnings show Q3 2026 net property income rose 4.6%, led by hotels, as the trust prepares to complete its Crowne Plaza Changi Airport sale.
· Original article
JNJ-6143 trial shows tumor responses in prostate cancer
JNJ-6143 trial results show tumor responses in advanced prostate cancer, offering an early clinical update on a drug acquired in J&J’s $3.05 billion Halda deal.
Charts and market data by TradingView. Availability and delays vary by exchange.